The spurious advance of antipsychotic drug therapy

  title={The spurious advance of antipsychotic drug therapy},
  author={Peter Tyrer and Tim Kendall},
  journal={The Lancet},
1 Laming. The Victoria Climbié inquiry: report of an inquiry by Lord Laming. January, 2003. nreport/ fi nreport.htm (accessed Nov 13, 2008). 2 BBC News Channel. Men found guilty of baby’s death. Nov 11, 2008. http:// (accessed Nov 17, 2008). 3 Gilbert R, Spatz Widom C, Browne K, Fergusson D, Webb E, Janson S. Burden and consequences of child maltreatment in high-income countries. Lancet 2008; published… Expand

Topics from this paper

Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis
Meta-analyses of randomised controlled trials in the early phase of psychosis looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects found no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile. Expand
Second generation antipsychotics reduce dropout rates compared with first generation antipsychotics
This report provides another argument for turning to new generation antipsychotics as fi rstline treatments for schizophrenia, albeit with the note of caution that post hoc meta-analyses cannot provide defi nitive answers. Expand
Towards a hermeneutic shift in psychiatry
  • P. Bracken
  • Medicine
  • World psychiatry : official journal of the World Psychiatric Association
  • 2014
It is argued that, if psychiatry is to be truly “evidence-based” in the authors' discipline, it needs a radical rethinking of its guiding epistemology: a move from reductionism to hermeneutics. Expand
Early intervention in psychosis: keeping the body in mind.
What Lester et al did find was that training could facilitate collaboration between GPs and the new early intervention services, and the obstacles were more about how they worked together. Expand
Psychiatry's identity crisis
It is understandable that Horton’s two lunch companions are nervous about competition for research talent, but the Crick will not aim to compete but to provide support for the whole UK biomedical research endeavour. Expand
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications
Consistent findings of no increased prescribing of risperidone post generics with limited specific demand-side measures suggests no ‘spillover’ effect from one class to another encouraging the preferential prescribing of generic atypical antipsychotic drugs. Expand
Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results.
These results show that, in the childhood–adolescent population, the presence of secondary effects begins to be observed from the first dose of the antipsychotic drug. Expand
Over-simplification and exclusion of non-conforming studies can demonstrate absence of effect: a lynching party?
  • D. Kingdon
  • Medicine, Psychology
  • Psychological Medicine
  • 2009
There is a small effect of CBT in severe depression but no effect in bipolar disorder and schizophrenia, and meta-analyses and reviews published so far have found favourably for CBT. Expand
Bennie, M. and Bishop, I. and Godman, B. and Barbui, C. and Raschi, E. and Campbell, S. and Miranda, J. and Gustafsson, L.L. (2013) Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?
Background: National and regional authorities in Scotland have introduced multiple measures to appreciably enhance prescribing efficiency for the proton pump inhibitors (PPIs), statins andExpand
Chapter 6 - Antipsychotic drugs
The effects of atypical antipsychotic drugs on carbohydrate intolerance and the development of diabetes show that they produce abnormalities in glucose tolerance by altering appetite regulation, insulin secretion and action, and the release of insulin counter-regulatory hormones, in particular leptin and ghrelin. Expand


Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data
A meta-analysis of data from randomised controlled trials that evaluated an SSRI versus placebo in participants aged 5-18 years and that were published in a peer-reviewed journal or were unpublished and included in a review by the Committee on Safety of Medicines indicated that risks could outweigh benefits of these drugs to treat depression in children and young people. Expand
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Expand
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Expand
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Treatment with perphenazine was less costly than treatment with second-generation antipsychotics with no significant differences in measures of effectiveness, but the trial was limited by a high dropout rate, and longer-term neurological and metabolic side effects require further study. Expand
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs. Expand
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost. Expand
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Expand
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients. Expand
Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
Conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotic drugs, according to the primary and sensitivity analyses. Expand
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
The first clinical studies indicate that two additional therapeutic targets may be obtained with risperidone in the monotherapy of schizophrenia and related disorders: very important contact and mood-elevating properties and extrapyramidal symptoms-free maintenance therapy. Expand